Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.
This search will output a list of trials for which you may be eligible based on the criteria you enter. If you would like help with this search, please contact us at firstname.lastname@example.org.
For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
|NCT03307785||Ib||Advanced solid tumors||Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer||View Drugs||Arizona, California, Florida, Michigan, New Mexico, Ohio, Oklahoma, South Carolina, Tennessee, Texas|
|Niraparib||MK4827, Zejula||PARP inhibitor|
|Bevacizumab||immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin||VEGF antagonist|
|Carboplatin||Paraplatin, Novoplatinum||DNA damaging agent|
|Paclitaxel||Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL||Microtubule stabilizer/mitotic inhibitor|
|TSR-022||Blocks TIM-3 inhibition of T cells|
|TSR-042||ANB011, anti-PD-1 monoclonal antibody TSR-042||Blocks PD-L1/2 inhibition of T cells|